Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE  Response to consultation
DATE  2018-04-23

TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear Dr. Kumar,

The Canadian Medical Association (CMA) thanks you for the opportunity to participate in the recently announced consultations on front-of-package labelling in Canada. This response presents the CMA’s perspectives on the potential effects of labelling as it relates to the right to health and the health system.

The CMA believes that pharmaceuticals are responsible for serious public health problems and that they must be held to higher standards of accountability and responsibility. They are responsible for ensuring that their products are safe and effective, and that people have access to them. They are also responsible for ensuring that people understand how to use their products safely and effectively.

The CMA recommends that the government take steps to ensure that people have access to health care. This includes ensuring that people have access to affordable prescription drugs.

Sincerely,

[Signature]

Dr. [Name]
Canadian Medical Association

[Further details and references can be added here if needed.]